CO2 digital angiography: a safer contrast agent for renal vascular imaging?

Although the new nonionic contrast agents are safer than ionic agents, renal insufficiency and even death still occur occasionally. Therefore, we have explored the use of carbon dioxide (CO2) as an alternative angiographic contrast agent used in combination with digital subtraction angiography. Clinical observations have been made in over 800 patients. The images obtained are of equivalent diagnostic quality compared with those using conventional iodinated contrast agents. Recent advances in imaging, including "stacking," provide images comparable with iodinated contrast. Very small vessels, equivalent to third-order branches of the renal artery, can be imaged satisfactorily with CO2. Occasional studies with CO2 yield information not apparent with iodinated contrast agents, including excellent visualization of arteriovenous shunts, collateral circulations, malignant tumors, and minute amounts of arterial bleeding. Many of the advantages and disadvantages of CO2 derive from its special physical and chemical properties. The advantages include no allergic potentiation and no renal metabolism of CO2, because CO2 is cleared by the lungs and does not recirculate. Other advantages include delivery by very small catheters because of the low viscosity of CO2, minimal discomfort on injection, and very low cost. However, the low-density and compressibility of CO2 poses some special problems. Imaging requires digital subtraction angiography with electronic enhancement and injections require an experienced investigator and, ideally, a dedicated CO2 injector. The dedicated CO2 injector provides calculated, controlled dosing and rates for injection, while excluding the possibility of air contamination. The buoyancy of CO2 inhibits good filling of dependent vessels. Accordingly, CO2 does not normally produce good nephrographic images, although proximal renal arteries are normally shown clearly. Experimental studies in dogs, whose renal arteries have been injected repeatedly with very large doses of CO2, demonstrate only transient changes in renal blood flow and no endothelial cell damage. However, these studies also showed clearly that renal ischemia can occur due to a "vapor lock" phenomenon if the kidney is positioned vertically above the injection site, and recurrent injections are given without time for absorption of the arterially delivered CO2 boluses. Uncontrolled studies in over 800 patients have confirmed that CO2 likely has a very low renal toxicity. At the University of Florida, CO2 is the radiologic contrast agent of choice in patients with renal insufficiency, especially those with diabetes mellitus, and in those with pre-existing allergy to iodinated contrast agents. Further controlled clinical studies are required to define the true clinical utility and safety of CO2 compared with conventional radiologic contrast agents.